Blood count and fasting blood glucose level in the assessment of prognosis and survival in advanced cervical cancer

• Autor(a) principal: Mota,Sâmela Daiere Soares
• Data de Publicação: 2022
• Outros Autores: Otaño,Sérgio Santana, Murta,Eddie Fernando Candido, Nomelini,Rosekeila
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista da Associação Médica Brasileira (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200234
• topic: Uterine cervical neoplasms; Blood cell count; Glucose; Prognosis; Survival

SUMMARY OBJECTIVE: The objective of this study was to verify whether the parameters of the blood count and the fasting glucose level before treatment are related to prognosis and survival in cervical cancer (IIB–IVB staging). METHODS: Patients with cervical cancer (stages IIB–IVB) were evaluated (n=80). Age, parity, staging, histological grade, histological type, hemoglobin, red blood cells, hematocrit, neutrophil, lymphocyte and platelet counts, red blood cell distribution width, neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, fasting glucose levels, overall survival, and disease-free survival were evaluated. The results of laboratory parameters were compared using the Mann–Whitney U test. Receiver operating characteristic curve was used to obtain the area under the curve and determine the best cutoff values for each parameter. Survival was verified by using the Kaplan–Meier method, followed by the log-rank test. The level of significance was ≤0.05. RESULTS: Regarding staging, lower hemoglobin values (p=0.0013), red blood cells (p=0.009), hematocrit (p=0.0016), higher leukocytes (p=0.0432), neutrophils (p=0.0176), platelets (p=0.0140), red blood cell distribution width (RDW) (p=0.0073), neutrophil–lymphocyte ratio (p=0.0039), platelet–lymphocyte ratio (p=0.0006), and fasting glucose level (p=0.0278) were found in IIIA–IVB compared with IIB staging. Shorter disease-free survival was associated with hemoglobin ≤12.3 g/dl (p=0.0491), hematocrit ≤38.5% (p=0.05), neutrophil–lymphocyte ratio >2.9 (p=0.0478), and platelet–lymphocyte ratio >184.9 (p=0.0207). Shorter overall survival was associated with hemoglobin ≤12.3 g/dl (p=0.0131), hematocrit ≤38.5% (p=0.0376), neutrophil–lymphocyte ratio >2.9 (p=0.0258), and platelet–lymphocyte ratio >184.9 (p=0.0038). CONCLUSION: The analysis of these low-cost and easily accessible parameters could be a way to monitor patients in order to predict treatment failures and act as early as possible.